Equipoise - Revision history

Lawrence: /* Bibliography */

2025-06-03T21:21:07Z

Bibliography

← Older revision		Revision as of 21:21, 3 June 2025
Line 33:		Line 33:
	=== Clinician and Patient Preferences ===		=== Clinician and Patient Preferences ===
	* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.		* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.
	* '''Solution''': Clear communication about equipoise during informed consent.		* '''Solution''': Clear communication about equipoise during [[informed consent]].

	=== Industry or Funding Bias ===		=== Industry or Funding Bias ===
Line 59:		Line 59:
	# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).		# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).
	# Futility is determined (e.g., the intervention is unlikely to show benefit).		# Futility is determined (e.g., the intervention is unlikely to show benefit).
	# External evidence resolves uncertainty, making continued randomization unethical.		# External evidence resolves uncertainty, making continued [[randomization]] unethical.

	== Conclusion ==		== Conclusion ==
	Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.		Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.
	~~==Bibliography==~~
	~~Freedman B: [https://pubmed.ncbi.nlm.nih.gov/3600702/ Equipoise and the ethics of clinical research]. N Engl J Med 1987, 317(3):141-14.~~
	----		----
			=== Bibliography ===

			# Freedman B. Equipoise and the [[ethics]] of clinical research. ''New England Journal of Medicine''. 1987;317(3):141–145.
			# Miller FG, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. ''Hastings Center Report''. 2003;33(3):19–28.
			# London AJ. Clinical equipoise: foundational requirement or fundamental error? In: Steinbock B, ed. ''The Oxford Handbook of Bioethics''. Oxford University Press; 2007:571–596.
			# Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. ''Cancer Control''. 2009;16(4):342–347.
			# Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits? ''Nature Medicine''. 2004;10(6):570–573.

			----
	''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 23:54, 3 April 2025

2025-04-03T23:54:15Z

← Older revision		Revision as of 23:54, 3 April 2025
Line 48:		Line 48:
	* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.		* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.

	=== COVID-19 Treatment Trials (RECOVERY Trial) ===		=== COVID-19 Treatment Trials ([https://www.recoverytrial.net/ RECOVERY Trial]) ===
	* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.		* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.
	* As evidence emerged, ineffective treatments were discontinued.		* As evidence emerged, ineffective treatments were discontinued.

	=== Breast Cancer Therapy (\|I-SPY 2 Trial) ===		=== Breast Cancer Therapy ([https://www.quantumleaphealth.org/for-patients/i-spy-trials/about-i-spy-2/ I-SPY 2 Trial]) ===
	* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.		* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.

Line 64:		Line 64:
	Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.		Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.
	==Bibliography==		==Bibliography==
	Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987, 317(3):141-14.		Freedman B: [https://pubmed.ncbi.nlm.nih.gov/3600702/ Equipoise and the ethics of clinical research]. N Engl J Med 1987, 317(3):141-14.
	----		----

	''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''		''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 23:52, 3 April 2025

2025-04-03T23:52:20Z

← Older revision		Revision as of 23:52, 3 April 2025
Line 52:		Line 52:
	* As evidence emerged, ineffective treatments were discontinued.		* As evidence emerged, ineffective treatments were discontinued.

	=== Breast Cancer Therapy (I-SPY 2 Trial) ===		=== Breast Cancer Therapy (\|I-SPY 2 Trial) ===
	* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.		* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.

Line 63:		Line 63:
	== Conclusion ==		== Conclusion ==
	Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.		Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.
			==Bibliography==
			Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987, 317(3):141-14.
			----

			''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence: /* Emerging Evidence During a Trial */

2025-03-30T15:25:15Z

Emerging Evidence During a Trial

← Older revision		Revision as of 15:25, 30 March 2025
Line 29:		Line 29:
	=== Emerging Evidence During a Trial ===		=== Emerging Evidence During a Trial ===
	* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.		* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.
	* '''Solution''': Implement interim analyses and Data Safety Monitoring Boards (DSMBs) to decide whether to stop or modify the trial.		* '''Solution''': Implement interim analyses and [[Data Safety and Monitoring Board\|Data Safety Monitoring Boards (DSMBs)]] to decide whether to stop or modify the trial.

	=== Clinician and Patient Preferences ===		=== Clinician and Patient Preferences ===

Lawrence: /* Informed Consent */

2025-03-30T15:22:07Z

Informed Consent

← Older revision		Revision as of 15:22, 30 March 2025
Line 19:		Line 19:
	* Ensures that the trial’s findings are genuinely informative for clinical decision-making.		* Ensures that the trial’s findings are genuinely informative for clinical decision-making.

	=== [[Informed Consent]] ===		=== [[Informed consent\|Informed Consent]] ===
	* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.		* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.

Lawrence: /* Informed Consent */

2025-03-30T15:21:22Z

Informed Consent

← Older revision		Revision as of 15:21, 30 March 2025
Line 19:		Line 19:
	* Ensures that the trial’s findings are genuinely informative for clinical decision-making.		* Ensures that the trial’s findings are genuinely informative for clinical decision-making.

	=== Informed Consent ===		=== [[Informed Consent]] ===
	* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.		* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.

Lawrence at 18:27, 24 March 2025

2025-03-24T18:27:01Z

Lawrence: Created page with "= What Is Equipoise? = '''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that: * Participants are not knowingly assigned to an inferior treatment. * The trial is scientifically justified and can provide valuable new evidence. == Types of Equipoise == # '''Clinical Equipoise''' (Expert C..."

2025-03-24T16:56:52Z

Created page with "= What Is Equipoise? = '''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that: * Participants are not knowingly assigned to an inferior treatment. * The trial is scientifically justified and can provide valuable new evidence. == Types of Equipoise == # '''Clinical Equipoise''' (Expert C..."

New page

= What Is Equipoise? =

'''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that:
* Participants are not knowingly assigned to an inferior treatment.
* The trial is scientifically justified and can provide valuable new evidence.

== Types of Equipoise ==
# '''Clinical Equipoise''' (Expert Consensus Equipoise) – Exists when there is genuine uncertainty among clinicians or researchers about the relative benefits and risks of treatment options.
# '''Personal (Individual) Equipoise''' – Exists when a single investigator is personally uncertain about which treatment is best. However, trials rely more on clinical equipoise rather than individual opinions.

= Why Is Equipoise Important in RCTs? =

== Ethical Justification ==
* Ensures that no participant is knowingly harmed by being assigned to an inferior treatment.
* Supported by international ethical guidelines, including the ''Declaration of Helsinki'' and ''Belmont Report''.

== Scientific Validity ==
* Without equipoise, an RCT may lack credibility, as the results would be biased towards a treatment already believed to be superior.
* Ensures that the trial’s findings are genuinely informative for clinical decision-making.

== Informed Consent ==
* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.

== Regulatory Approval & Ethical Oversight ==
* Ethical review boards and regulatory agencies assess whether equipoise exists before approving a trial.

= Challenges to Maintaining Equipoise =

== Emerging Evidence During a Trial ==
* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.
* '''Solution''': Implement interim analyses and Data Safety Monitoring Boards (DSMBs) to decide whether to stop or modify the trial.

== Clinician and Patient Preferences ==
* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.
* '''Solution''': Clear communication about equipoise during informed consent.

== Industry or Funding Bias ==
* Pharmaceutical or industry-sponsored trials may lack true equipoise if there is a strong belief in the superiority of the new treatment.
* '''Solution''': Independent trial oversight committees and transparent study design.

== Placebo-Controlled Trials ==
* Using a placebo instead of an active comparator may challenge equipoise, especially if an effective standard treatment exists.
* '''Solution''': Placebos are only ethical if there is no proven effective therapy or if withholding treatment does not cause harm.

= Examples of Equipoise in RCTs =

== Hypertension Treatment Trials ==
* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.

== COVID-19 Treatment Trials (RECOVERY Trial) ==
* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.
* As evidence emerged, ineffective treatments were discontinued.

== Breast Cancer Therapy (I-SPY 2 Trial) ==
* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.

= Loss of Equipoise: When to Stop an RCT? =
RCTs may be stopped early if:
# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).
# Futility is determined (e.g., the intervention is unlikely to show benefit).
# External evidence resolves uncertainty, making continued randomization unethical.

= Conclusion =
Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.

← Older revision		Revision as of 18:27, 24 March 2025
Line 1:		Line 1:
	= What Is Equipoise? =		== What Is Equipoise? ==

	'''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that:		'''Equipoise''' refers to a state of genuine uncertainty within the expert medical community regarding whether one treatment is superior to another. It is a fundamental ethical principle in randomized controlled trials (RCTs), ensuring that:
Line 5:		Line 5:
	* The trial is scientifically justified and can provide valuable new evidence.		* The trial is scientifically justified and can provide valuable new evidence.

	== Types of Equipoise ==		=== Types of Equipoise ===
	# '''Clinical Equipoise''' (Expert Consensus Equipoise) – Exists when there is genuine uncertainty among clinicians or researchers about the relative benefits and risks of treatment options.		# '''Clinical Equipoise''' (Expert Consensus Equipoise) – Exists when there is genuine uncertainty among clinicians or researchers about the relative benefits and risks of treatment options.
	# '''Personal (Individual) Equipoise''' – Exists when a single investigator is personally uncertain about which treatment is best. However, trials rely more on clinical equipoise rather than individual opinions.		# '''Personal (Individual) Equipoise''' – Exists when a single investigator is personally uncertain about which treatment is best. However, trials rely more on clinical equipoise rather than individual opinions.

	= Why Is Equipoise Important in RCTs? =		== Why Is Equipoise Important in RCTs? ==

	== Ethical Justification ==		=== Ethical Justification ===
	* Ensures that no participant is knowingly harmed by being assigned to an inferior treatment.		* Ensures that no participant is knowingly harmed by being assigned to an inferior treatment.
	* Supported by international ethical guidelines, including the ''Declaration of Helsinki'' and ''Belmont Report''.		* Supported by international ethical guidelines, including the ''Declaration of Helsinki'' and ''Belmont Report''.

	== Scientific Validity ==		=== Scientific Validity ===
	* Without equipoise, an RCT may lack credibility, as the results would be biased towards a treatment already believed to be superior.		* Without equipoise, an RCT may lack credibility, as the results would be biased towards a treatment already believed to be superior.
	* Ensures that the trial’s findings are genuinely informative for clinical decision-making.		* Ensures that the trial’s findings are genuinely informative for clinical decision-making.

	== Informed Consent ==		=== Informed Consent ===
	* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.		* Participants must be truthfully informed that the trial is being conducted because the best treatment option is unknown.

	== Regulatory Approval & Ethical Oversight ==		=== Regulatory Approval & Ethical Oversight ===
	* Ethical review boards and regulatory agencies assess whether equipoise exists before approving a trial.		* Ethical review boards and regulatory agencies assess whether equipoise exists before approving a trial.

	= Challenges to Maintaining Equipoise =		== Challenges to Maintaining Equipoise ==

	== Emerging Evidence During a Trial ==		=== Emerging Evidence During a Trial ===
	* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.		* Ongoing trials may generate new data that favor one treatment, disrupting equipoise.
	* '''Solution''': Implement interim analyses and Data Safety Monitoring Boards (DSMBs) to decide whether to stop or modify the trial.		* '''Solution''': Implement interim analyses and Data Safety Monitoring Boards (DSMBs) to decide whether to stop or modify the trial.

	== Clinician and Patient Preferences ==		=== Clinician and Patient Preferences ===
	* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.		* Some clinicians or patients may strongly prefer one treatment, leading to lower recruitment or non-adherence.
	* '''Solution''': Clear communication about equipoise during informed consent.		* '''Solution''': Clear communication about equipoise during informed consent.

	== Industry or Funding Bias ==		=== Industry or Funding Bias ===
	* Pharmaceutical or industry-sponsored trials may lack true equipoise if there is a strong belief in the superiority of the new treatment.		* Pharmaceutical or industry-sponsored trials may lack true equipoise if there is a strong belief in the superiority of the new treatment.
	* '''Solution''': Independent trial oversight committees and transparent study design.		* '''Solution''': Independent trial oversight committees and transparent study design.

	== Placebo-Controlled Trials ==		=== Placebo-Controlled Trials ===
	* Using a placebo instead of an active comparator may challenge equipoise, especially if an effective standard treatment exists.		* Using a placebo instead of an active comparator may challenge equipoise, especially if an effective standard treatment exists.
	* '''Solution''': Placebos are only ethical if there is no proven effective therapy or if withholding treatment does not cause harm.		* '''Solution''': Placebos are only ethical if there is no proven effective therapy or if withholding treatment does not cause harm.

	= Examples of Equipoise in RCTs =		== Examples of Equipoise in RCTs ==

	== Hypertension Treatment Trials ==		=== Hypertension Treatment Trials ===
	* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.		* Equipoise existed when comparing beta-blockers vs. ACE inhibitors before clear superiority was established.

	== COVID-19 Treatment Trials (RECOVERY Trial) ==		=== COVID-19 Treatment Trials (RECOVERY Trial) ===
	* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.		* At the start, there was clinical uncertainty about the effectiveness of treatments like dexamethasone and hydroxychloroquine.
	* As evidence emerged, ineffective treatments were discontinued.		* As evidence emerged, ineffective treatments were discontinued.

	== Breast Cancer Therapy (I-SPY 2 Trial) ==		=== Breast Cancer Therapy (I-SPY 2 Trial) ===
	* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.		* Maintained equipoise by using adaptive platform trial design, allowing new therapies to be tested without bias toward a preferred treatment.

	= Loss of Equipoise: When to Stop an RCT? =		== Loss of Equipoise: When to Stop an RCT? ==
	RCTs may be stopped early if:		RCTs may be stopped early if:
	# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).		# One treatment is proven superior or harmful (e.g., early stopping due to clear survival benefits).
Line 61:		Line 61:
	# External evidence resolves uncertainty, making continued randomization unethical.		# External evidence resolves uncertainty, making continued randomization unethical.

	= Conclusion =		== Conclusion ==
	Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.		Equipoise is critical for conducting ethical and scientifically valid RCTs. It ensures that trials are justified, patients are protected, and results contribute meaningfully to medical knowledge. Maintaining equipoise requires careful trial design, continuous monitoring, and transparent reporting to uphold ethical integrity.